Pharmacological inhibition of calcineurin by CsA blocks NFATc1 activation as well as its nuclear translocation; and more importantly, CsA treatment sensitizes pancreatic cancer cells to P-S. The gene discussed is NFATC1; the disease is pancreatic neoplasm.